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a  b  s  t  r  a  c  t
In regions  where  hepatitis  B  virus  (HBV)  is endemic,  perinatal  transmission  is  common.  Infected  newborns
have  a 90%  chance  of developing  chronic  HBV  infection,  and  1 in  4 will  die  prematurely  from  HBV-related
liver  disease.  In  2010,  the Hepatitis  B Foundation  and  the  Haimen  City  CDC  launched  the  Gateway  to
Care  campaign  in Haimen  City,  China  to  improve  awareness,  prevention,  and control  of  HBV  infection
citywide.  The  campaign  included  efforts  to prevent  perinatal  HBV  transmission  by screening  all  pregnant
women  for  hepatitis  B surface  antigen  (HBsAg),  following  those  who  tested  positive,  and  administering
immunoprophylaxis  to  their  newborns  at birth.  Of 5407  pregnant  women  screened,  185 were  conﬁrmed
HBsAg-positive  and  followed  until  delivery.  At  age one,  175  babies  were  available  for  follow  up testing.
Of  those,  137  tested  negative  for  HBsAg  and  positive  for antibodies  to HBsAg,  indicating  protection.  An
additional  34  HBsAg-negative  babies  also  tested  negative  for  antibodies  to  HBsAg  or had  indeterminate
test  results,  were  considered  to have  had  inadequate  immune  responses  to the  vaccine,  and  were  given
a booster  dose.  A higher  prevalence  of  nonresponse  to HBV  vaccine  was  observed  among  babies  born  to
hepatitis  B  e antigen  (HBeAg)-positive  mothers  and  mothers  with  high  HBV  DNA  titers.  The  remaining
4  babies  tested  positive  for HBsAg  and  negative  for  antibodies,  indicative  of active  HBV  infection.  The
mothers  of  all  4 had viral  loads  ≥8 × 106 copies/ml  in the third  trimester.  Although  inadequate  response
or  nonresponse  to HBV  vaccine  was  more  common  among  babies  born  to  HBeAg-positive  and/or  high
viral  load  mothers,  these risk factors  did  not  completely  predict  nonresponsiveness.  All babies  born  to
HBV-infected  mothers  should  be tested  upon  completion  of the  vaccine  series  to ascertain  adequate
protection.  Some  babies  of HBeAg-positive  mothers  with  high  viral  load  may  still  become  HBV  infected
despite  timely  immunoprophylaxis  with  HBV  vaccine  and  HBIG.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. IntroductionChronic hepatitis B virus (HBV) infection is a major cause of
orbidity and mortality globally, causing approximately 600,000
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aimen City Center for the Health of Women  and Children; IQR, interquartile range.
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annual deaths due to cirrhosis, liver failure, or liver cancer [1].
HBV is endemic in many areas of the world, including Asia, Africa,
and the Paciﬁc Islands. In these regions, mother to child (peri-
natal) transmission is a common route of infection, due to blood
exchange during the childbirth process [2]. In the absence of effec-
tive immunoprophylaxis, perinatal HBV transmission rates are 20%
to 95%, depending on maternal HBV viral load and hepatitis B e anti-
gen (HBeAg) status [3,4]. A baby infected with HBV perinatally has
a 90% chance of developing chronic HBV infection (less than 10%
of people infected as adults develop chronic HBV infections) [5].
One in four adults who were infected at birth will die prematurely
from HBV-related liver disease [6]. There are effective methods of
preventing perinatal transmission, including screening pregnant
women for HBV, administering HBV vaccine to babies beginning
at birth, and administration of hepatitis B immune globulin (HBIG)
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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t birth for babies born to infected mothers [7]. Administration of
ntivirals in late pregnancy to mothers with high viral loads has also
een shown to be effective in preventing perinatal transmission [4].
he recommended components of perinatal HBV prevention pro-
rams differ by region [8,9]. In 2010, the Ministry of Health in China
ssued a recommendation that all pregnant women  be screened for
BV infection and that their infants receive immunoprophylaxis at
irth [10].
In 2010, the Haimen City (China) Center for Disease Control and
revention (HCCDC), in collaboration with the Hepatitis B Founda-
ion, launched “Gateway to Care,” a multi-year city-wide campaign
ocused on improving prevention and control of HBV infection, and
ncouraging the adoption of evidence-based HBV infection pre-
ention measures. The campaign included HBV education of the
eneral public, leaders, and medical care providers [11]. A perinatal
BV prevention program was an integral part of the campaign, and
ncluded the establishment of a centralized registration system for
ll pregnant women, testing pregnant women for HBV infection,
nd delivery of immunoprophylaxis to newborns. In this report
e describe the outcomes of perinatal HBV prevention efforts in
regnant women screened for HBV in Haimen City, China over a
2-month period.
. Methods
.1. Enhanced screening and prevention initiative
As part of the Gateway to Care city-wide campaign to raise
wareness and improve prevention services for hepatitis B in
aimen City, China [11], the HCCDC enhanced its efforts to screen
ll pregnant city residents for HBV infection, and to follow those
omen who test positive until the time of delivery when immuno-
rophylaxis is made available for all infants. Routine prenatal blood
esting for hepatitis B surface antigen (HBsAg), and collection of
emographic and risk factor data was done by the Haimen City
enter for the Health of Women  and Children (HCHWC, a pub-
ic health agency under the Haimen City Health Bureau), usually
uring the ﬁrst trimester. Women  who initially tested positive for
BsAg were referred to the HCCDC for repeat HBsAg testing, and
nalysis of additional HBV markers which included HBeAg; anti-
odies to HBsAg, HBeAg, and hepatitis B core antigen or HBcAg
anti-HBs, anti-HBe, and anti HBc); and circulating HBV DNA lev-
ls (viral load). The women also received education and counseling
egarding their test results. The HCCDC recommends that all babies
orn to HBsAg-positive mothers receive the ﬁrst dose of HBV vac-
ine and 100 IU of hepatitis B immune globulin (HBIG) at their birth
ospital within 12 to 24 h of birth. Delivery hospitals routinely test
or HBV markers when a pregnant woman is admitted before deliv-
ry, and free birth dose and HBIG are to be given to the newborn if
he woman tests positive. For this study, each woman who was
dentiﬁed as HBsAg-positive during prenatal screening was also
iven a ﬂash card at her late pregnancy follow-up appointment to
ring with her to the delivery hospital as a reminder. The babies
orn to HBsAg-positive mothers also received follow up HBV test-
ng around 12 months of age, after completing the routine 3-dose
ourse of HBV vaccination. HBV vaccine and HBIG were provided
y the Haimen City government without charge to the patients and
ere administered at the birth hospital, where appropriate refrig-
ration was available. All births in this study occurred in hospitals
n Haimen City..2. Laboratory analysis
Routine immunoassays for HBV markers (HBsAg, HBeAg, anti-
Bs, anti-HBe, anti-HBc) were performed at HCCDC using the3 (2015) 3010–3015 3011
Hepatitis B virus HBsAg (or other markers) Testing Kit manu-
factured by Shanghai Kehua Bioengineering Company, Ltd. HBV
viral load was  quantitated using the Hepatitis B Virus DNA
PCR-Fluorescence Detection Kit real time PCR (Shanghai Kehua
Bioengineering Company, Ltd) via real time PCR on the FluoCycle
Real-time PCR Detection System manufactured by Shanghai Kehua
Laboratory System Company, Ltd. This assay has a lower limit of
detection of ∼500 copies/ml.
2.3. Immunoprophylaxis
HBV vaccine administered to infants was a 10 g dose from
Dalian Hissen Bio-pharm Company, Ltd. HBIG was administered as
a single 100 IU dose from Sichuan Yuanda Shuyang Pharmaceutical
Company, Ltd.
2.4. Data analysis
Records from women seeking prenatal care from HCHWC from
July 1, 2011 through June 30, 2012 were abstracted and reviewed
for program evaluation purposes and provided in fully anonymized
form for the study reported herein. Ethical approval for this analysis
of the program data was provided by the Ethics Review Committee
of Haimen City.
Statistical analyses were performed using SAS v 9.3. For continu-
ous variables, Wilcoxon rank sum test was used for variables where
the interquartile range (IQR) is given, due to non-normality of dis-
tributions. Where mean and standard deviation are given, Student’s
t-test was  used. For comparison of proportions, Fisher’s exact test
was used.
3. Results
3.1. Mothers
Prenatal care and delivery records for 5407 women screened
for HBsAg by HCHWC were reviewed. Of these, 5129 (94.9%) tested
HBsAg-negative and 278 (5.1%) initially tested positive (Fig. 1).
Demographically, the women  whose initial HBV tests were positive
were slightly younger than those testing negative, but were similar
in level of education, number of previous births, and type of delivery
in the index pregnancy (Table 1). (Note that the Caesarean sec-
tion rate, although high, is consistent with the general rate across
China.) [12]. There were statistically signiﬁcant differences in the
frequency of self-reported past HBV vaccine and previous HBV  test-
ing between the women with initial positive vs. negative HBsAg
tests. Women  who  tested initially positive for HBsAg were less
likely to report previous HBV vaccination, and more likely to report
previous HBV testing. Among those who reported a previous (pre-
pregnancy) HBV test, the women with initially positive HBsAg tests
were more likely to report that the previous test was  positive, and
much less likely to report not knowing the result of their previous
HBsAg test than women  who  tested HBsAg-negative (Table 1).
The 278 women  with initially positive HBsAg tests were referred
to the HCCDC for repeat testing in the third trimester. Of these, 185
(66.5%, or 3.4% of the original 5407 screened) were conﬁrmed pos-
itive on the second test, 12 (4.3%) tested HBsAg-negative, and 81
(29.1%) did not return for repeat testing (Fig. 1). The 185 women
conﬁrmed to be HBsAg positive upon repeat testing were fur-
ther evaluated for the presence of anti-HBc, HBeAg, and anti-HBe,
and circulating HBV DNA levels in the third trimester. In samples
from 127 (68.6%) of these women, HBV viral loads were below
the assay’s limit of detection (500 copies/ml). The median viral
load for the remaining 58 women  was 1.1 × 107 copies/ml (IQR
1.6 × 105–2.5 × 107). The distribution of HBV viral load in the 185
conﬁrmed HBsAg-positive mothers is shown in Fig. 2. Forty-nine of
3012 A.A. Evans et al. / Vaccine 33 (2015) 3010–3015
Fig. 1. Summary of HBV screening results for 5407 pregnant women  seeking prenatal care from HCHWC from July 1, 2011 through June 30, 2102. Infants born to HBsAg-
positive mothers were given HBV vaccine and HBIG within 24 h of birth (see Fig. 3). At approximately one year of age, 175 infants were screened for HBsAg and further
evaluated as appropriate.
Table 1
Demographics and self-reported pre-pregnancy HBV vaccine and HBV testing status among women  with initial positive vs. negative HBsAg tests.
Initial test HBsAg-negative (N = 5129) Initial test HBsAg-positive (N = 278) p-Value
Demographics
Maternal age (mean ± SD) 25.0 (4.3) 26.1 (4.7) <0.0001
Education > high school N (%) 2094 (40.8) 109 (39.2) 0.64
Delivery (index pregnancy) N (%)
Vaginal 102 (40.0) 2150 (45.1) 0.11
Caesarean section 153 (60.0) 2616 (54.9)
Nulliparous N (%) 4065 (79.3) 213 (76.6) 0.29
Self  reported pre-pregnancy HBV status
Previous HBV vaccine N (%)
Yes 2208 (43.1) 90 (32.4) 0.0005
No  1367 (26.7) 99 (35.6)
Don’t know 1554 (30.3) 89 (32.0)
Previous HBV test N (%) <0.0001
Yes  1243 (24.3) 163 (58.6)
No  3112 (60.7) 93 (33.5)
Don’t know 774 (15.1) 22 (7.9)
Previous HBV test result N (%)a <0.0001
Positive 6 (0.5) 143 (88.3)
Negative 1054 (84.8) 17 (10.5)
1
H
p
H
3
(
p
a
(
a
v
a
d
A
c
mDon’t know 183 (14.7) 
a Among those self-reporting both test and result.
85 (26.5%) women tested HBeAg-positive, and 136 (73.5%) were
BeAg-negative. Viral load was signiﬁcantly higher in the HBeAg-
ositive (median 1.2 × 107, IQR 8.7 × 105–3.6 × 107) compared to
BeAg-negative women (median 0, IQR 0-0) (p < 0.0001).
.2. Infants
Delivery hospital records were available for review for 183
98.9%) of 185 babies born to mothers conﬁrmed to be HBsAg-
ositive. All 183 babies (100%) received both hepatitis B vaccine
nd HBIG within 23 h of birth (Fig. 3). The median time was 2 h
IQR 1–4) after birth for vaccine administration, and 1 h (IQR 1–2)
fter birth for HBIG. For comparison, a related retrospective sur-
ey found that 98.9% of the babies born to HBV-infected women,
nd 98.5% of babies born to non-infected women, received birth
ose of HBV vaccine in 2010 (Haimen City CDC unpublished data).
ll 183 babies completed the full 3-dose schedule for HBV vac-
ine as recommended for all infants in Haimen City. Follow up HBV
arker testing was recommended by HDCDC for these 183 babies2 (1.2)
born to conﬁrmed HBsAg-positive mothers, after completion of the
vaccine series. Testing was done, on average, 365 days after birth
(standard deviation 67, range 290–659 days). Serologic test results
for HBsAg, anti-HBs, anti-HBc, and HBeAg from 175 babies were
available. (Multiple attempts were made to test all babies born
to infected women in the cohort, however 10 babies were out of
town with their parents who work in other cities and they were
unavailable for further testing.)
Four babies (2.3%) were found to be HBsAg-positive (indicative
of active HBV infection), and all four were also HBeAg-positive,
anti-HBc-positive, and had no detectable antibodies to HBsAg. All
four of these HBsAg-positive babies had received HBV vaccine and
HBIG no more than 11 h after birth. The mothers of all four HBsAg-
positive babies were HBeAg-positive and had viral loads between
8 × 106 and 5 × 107 copies/ml in the third trimester (Table 2). Moth-
ers whose babies became HBsAg-positive had higher viral loads
than those whose babies remained negative (median 2.4 × 107
vs. 0, p = 0.0012) and were more likely to be HBeAg-positive
(100% vs. 25.2%, p = 0.005). The transmission rate among babies of
A.A. Evans et al. / Vaccine 33 (2015) 3010–3015 3013
Table  2
Maternal and infant characteristics for 6 infants found to be HBsAg-positive and/or anti-HBc positive.
Maternal HBV DNA (copies/ml) Maternal HBeAg Vaccine/HBIG timing
(hours after delivery)
Delivery method Infant follow-up testing
(days after birth)
Baby HBsAg-positive/anti-HBc-positive/anti-HBs-negative
1  8 × 106 + 11 Cesarean 338
2  2 × 107 + 2 Cesarean 313
3  3 × 107 + 1 Vaginal 453
4  5 × 107 + 1 Vaginal 341
Baby  anti-HBc-positive/HBsAg-negative/anti-HBs-positive
1  Undetected − 1 
2  1 × 105 + 3 
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hig. 2. Distribution of maternal HBV DNA levels during the 3rd trimester for HBsAg-
ositive women. Stars indicate the viral load of 4 mothers whose babies tested
BsAg-positive at one year old.
BeAg-positive mothers was 8.2% (4/49, 95%CI 3.2–19.2%). Within
he group of HBeAg-positive mothers, however, there was  no sta-
istically signiﬁcant difference in median maternal viral load for
he HBsAg-positive vs. -negative babies (medians 2.4 × 107 vs.
.2 × 107, p = 0.46).
A total of 171 babies tested HBsAg-negative. Of these, 137
80.1%) tested anti-HBs positive (indicative of protection from
BV). Two of the babies testing anti-HBs-positive were also anti-
Bc-positive and were therefore considered to have had and
leared transient infections (Table 2). Of the 34 anti-HBs-negative
abies, 9 (26.5%) had indeterminate tests for anti-HBs, and 25
73.5%) were anti-HBs-negative. Although it is possible that they
ad had protective levels of antibody that had waned by the time
40%
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Fig. 3. Cumulative distribution of time of HBV vaccine and HBIG administration tCesarean 302
Cesarean 659
they were tested for anti-HBs, for the purposes of this study these
34 babies were considered to have inadequate immune responses
to the HBV vaccine and were referred for booster doses. The babies
with inadequate response to vaccination were more likely to have
HBeAg-positive mothers (relative risk 1.7, 95% CI 1.0–3.0), and
higher maternal HBV viral loads than babies who seroconverted to
anti-HBs-positive after vaccination (p = 0.04) (Table 3). The median
viral load was lower than the limit of detection for both groups, but
the IQR was  broader for those with inadequate response (Table 3).
Delivery records were also sought for the 81 initially HBsAg-
positive mothers who  did not go to the HCCDC for conﬁrmatory
HBsAg testing during their pregnancies. Of these 18 (22.2%) had
no records found, indicating that they did not deliver in a Haimen
City hospital, or did not complete the pregnancy. Of the 63 (77.8%)
with birth records, all babies received both the birth dose of HBV
vaccine and one dose of HBIG administered within 24 h of birth,
but these babies were not followed for HBV infection and vaccine
response endpoints. Mothers who had not returned for conﬁrma-
tory HBsAg testing were less likely to be nulliparous than those
who did (67.9% vs. 80.0%, p = 0.03) but did not differ signiﬁcantly
on other demographic variables.
4. Discussion
Public health disease prevention programs usually work best
when there is awareness of the problem and engagement in the
solution at multiple levels of the health care system. This paper
reports the outcomes of enhanced perinatal HBV prevention efforts
in Haimen City, China. These efforts were instituted as part of a
focused campaign to raise public and provider awareness of HBV
infection, its impact in the population, and the available tools for
prevention and control of infection. Along with education of the
public and health care providers, a high priority was placed on the
screening of all pregnant women, follow-up and education for all
those found to be infected, and delivery of post-exposure prophy-
laxis to their newborns. HBV perinatal prophylaxis for infants born
to infected mothers, including both HBV vaccine and HBIG within
12 to 24 h of birth, was shown to be feasible and very effective in
4 15 16 17 18 19 20 21 22 23 24
irth
Vaccine
HBIG
o babies born to HBsAg-positive mothers 1 to 24 h after delivery. (N = 183).
3014 A.A. Evans et al. / Vaccine 33 (2015) 3010–3015
Table 3
Maternal characteristics for babies with adequate vs. non/indeterminate antibody response to 3 doses of HBV vaccine. (All mothers were conﬁrmed HBsAg-positive.).
Vaccine responders (N = 137) Vaccine nonresponders (N = 34)a p
Mother HBeAg-positive [N (%)]b 30 (21.9) 13 (38.2) 0.08
Mother HBV viral load median (IQR)b <5 × 102 (<5 × 102–2 × 103) <5 × 102 (<5 × 102–9 × 105) 0.04
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[a Excluding HBsAg-positive babies (N = 4).
b From maternal testing in third trimester.
reventing perinatal transmission in this population, where it has
een instituted as part routine care in an enhanced public health
rogram [11].
For the group reported in this study, which had especially good
dherence to a standard immunoprophylaxis protocol, the over-
ll infection rate among the babies born to infected women  was
ow (4/175 babies screened, 2.3%). These results are similar to that
een in other studies and speak to the fact that the intervention
HBV vaccine and HBIG) was highly successful, preventing perinatal
ransmission of HBV infection in 97.7% of babies screened [13–16].
ll of the HBsAg-positive babies were born to mothers who  were
BeAg-positive (4/49, 8.2%), and had maternal viral loads ≥8 × 106
opies/ml in the third trimester. Follow-up testing of babies showed
hat among those not infected, there is a higher prevalence of non-
esponse to HBV vaccines among those born to HBeAg+ mothers.
oreover, in the two babies who may  have experienced transient
nfections, one was born to a mother who was HBeAg-negative and
ad a viral load lower than the detection limit of the assay. As noted
bove, public health ofﬁcials administered booster doses of vac-
ine to all babies showing inadequate response to the ﬁrst course
f vaccine. Of 18 babies retested thus far, 15 (83.3%) had converted
o anti-HBs-positive, indicating a response to the booster vaccine.
This analysis is based on administrative data collected by the
CCDC for program evaluation. There was no control or untreated
roup, so we cannot know directly what the transmission rate
ould have been without the immunoprophylaxis. Women  who
hose to participate in this program were similar to those who
nitially tested HBsAg-positive but did not participate except that
he non-participants were less likely to be nulliparous. Perinatal
ransmission rates have been estimated at 85% and 31% for HBeAg-
ositive and -negative mothers, respectively [17]. Our study and
thers have shown that this transmission rate is greatly reduced
ith effective and timely immunoprophylaxis at birth. In this
ery high risk population, with a maternal HBsAg prevalence >5%
nd HBeAg prevalence among HBsAg-positives >26%, the potential
mpact of timely intervention is high, as it would be for other similar
opulations worldwide. It appears, however, that even with opti-
al  timing of this intervention, some infections still occur, possibly
n utero [18,19], 4/175 babies tested (2.3%) in our study. In some
arts of the world, the use of antiviral medications in late pregnancy
s becoming a more common practice, especially for mothers with
igh viral load and detectable HBeAg. With the use of antivirals,
owever, consideration of the appropriateness of long-term treat-
ent and the risk of postpartum ﬂare or viral load rebound must
e a factor in the decision [4]. (In this study, there were no women
eceiving antiviral treatment during pregnancy and it is not offered
y physicians in Haimen City.)
HBV perinatal prevention programs should ideally include
ollow-up of babies born to infected mothers to detect infections
nd monitor vaccine response. Follow-up of infants is not a rou-
ine practice and for this study, signiﬁcant efforts were made to
est the majority of babies born to infected women within the
ne-year period. In this study, we noted a high proportion (∼20%)
f babies who received timely immunoprophylaxis at birth and
ested either negative or indeterminate for anti-HBs at approxi-
ately 1 year of age, consistent with ﬁndings in another studies
20,21]. Public health ofﬁcials from HCCDC are now following thesebabies after delivery of booster doses of vaccine. It is important to
note that inadequate response or nonresponse to HBV vaccine was
more common among babies born to HBeAg-positive and/or high
viral load mothers, but these risk factors did not completely pre-
dict nonresponsiveness. It is important to further evaluate infected
pregnant women for their HBeAg status and viral load, and to do
follow-up antibody testing for all babies born to infected mothers
to ascertain whether they are adequately protected from infection
in the future.
In many ways, the community setting in Haimen City, China dur-
ing this time period was ideal for effective perinatal prevention.
As part of the Gateway to Care campaign, the general popula-
tion’s awareness and knowledge of HBV infection had been raised,
and health care providers throughout the community had received
training on HBV prevention and treatment. Particular care was
taken to make personnel at all levels of the medical care system
aware of the need to screen pregnant women and perform appro-
priate and timely immunoprophylaxis for their babies. To replicate
the success of the Haimen City campaign elsewhere, there should be
a similar commitment to public and provider education, availabil-
ity of immunoprophylaxis at delivery, and continued monitoring of
both mothers and babies to identify HBV infection, prevent perina-
tal transmission, and ensure vaccine protection of babies.
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